Asterand To Buy BioSeek
Asterand PLC (LSE: ATD) has acquired BioSeek Inc., a Burlingame, Calif. drug developer that uses predictive human biology. The deal includes a $1 million up-front payment in Asterand stock, and up to $13 million in earnouts ($10m in cash). BioSeek had raised around $28 million in VC funding, from Amylin Pharmaceuticals,Bay City Capital, Fremont Ventures and Vanguard Ventures.
20 November 2009•5 mins read
